SCHEMBL26460459

SCHEMBL26460459

CC(P)(P)COc1ccc(-c2ccc3cnc(C(C)(F)P)n3c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 13/20 0.56
SCN1A P35498 1/20 0.34
SCN2A Q99250 1/20 0.34
DGAT1 O75907 3/20 0.34
CYP1A2 P05177 1/20 0.33
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HSD17B10 Q99714 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
SSTR4 P31391 1/20 0.31
KCNH2 Q12809 1/20 0.31
SCN10A Q9Y5Y9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26462424 0.93 SCN5A (0.56) SCN5ASCN1ASCN2ADGAT1CYP1A2
SCHEMBL26460368 0.84 SCN5A (0.61) SCN5ASCN1ASCN2ADGAT1CYP1A2
SCHEMBL26460337 0.82 SCN5A (0.63) SCN5ASCN1ASCN2ACYP1A2KCNH2
SCHEMBL936582 0.82 SCN5A (0.73) SCN5ASCN1ASCN2ADGAT1CYP1A2
SCHEMBL26460440 0.79 SCN5A (0.64) SCN5ASCN1ASCN2AKDM4EMEN1
SCHEMBL26460261 0.78 SCN5A (0.60) SCN5ASCN1ASCN2AKDM4EMEN1
SCHEMBL26460412 0.76 SCN5A (0.61) SCN5ASCN1ASCN2AKDM4EMEN1
SCHEMBL26461696 0.75 SCN5A (0.60) SCN5ASCN1ASCN2AKDM4EMEN1
SCHEMBL26462859 0.75 SCN5A (0.67) SCN5ASCN1ASCN2ACYP1A2KDM4E
SCHEMBL932813 0.75 SCN5A (0.75) SCN5ASCN1ASCN2ACYP1A2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230134428-A1 FUSED HETEROARYL COMPOUNDS, AND METHODS THEREOF FOR TREATING DISEASES, DISORDERS, AND CONDITIONS RELATING TO ABERRANT FUNCTION OF A SODIUM CHANNEL PRAXIS PRECISION MEDICINES, INC. 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230134428-A1 FUSED HETEROARYL COMPOUNDS, AND METHODS THEREOF FOR TREATING DISEASES, DISORDERS, AND CONDITIONS RELATING TO ABERRANT FUNCTION OF A SODIUM CHANNEL SCN1A, SCN3A, SCN2A SCN5A 7/4885SCN1A 1/4885SCN2A 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.